JP2022549140A - 遺伝子療法組成物および不整脈源性右心室心筋症の治療 - Google Patents

遺伝子療法組成物および不整脈源性右心室心筋症の治療 Download PDF

Info

Publication number
JP2022549140A
JP2022549140A JP2022517343A JP2022517343A JP2022549140A JP 2022549140 A JP2022549140 A JP 2022549140A JP 2022517343 A JP2022517343 A JP 2022517343A JP 2022517343 A JP2022517343 A JP 2022517343A JP 2022549140 A JP2022549140 A JP 2022549140A
Authority
JP
Japan
Prior art keywords
pkp2
gene therapy
vector
nucleic acid
viral
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022517343A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022549140A5 (cg-RX-API-DMAC7.html
Inventor
ヴォイト,トーマス
デュモンセオー,ジュリー
エリオット,ペリー
マリオット,ヴァージニー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCL Business Ltd
Original Assignee
UCL Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCL Business Ltd filed Critical UCL Business Ltd
Publication of JP2022549140A publication Critical patent/JP2022549140A/ja
Publication of JP2022549140A5 publication Critical patent/JP2022549140A5/ja
Priority to JP2026021870A priority Critical patent/JP2026116276A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4716—Muscle proteins, e.g. myosin, actin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14145—Special targeting system for viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022517343A 2019-09-20 2020-09-21 遺伝子療法組成物および不整脈源性右心室心筋症の治療 Pending JP2022549140A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2026021870A JP2026116276A (ja) 2019-09-20 2026-02-13 遺伝子療法組成物および不整脈源性右心室心筋症の治療

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962903103P 2019-09-20 2019-09-20
US62/903,103 2019-09-20
PCT/EP2020/076290 WO2021053222A1 (en) 2019-09-20 2020-09-21 Gene therapy composition and treatment of right ventricular arrythmogenic cardiomyopathy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2026021870A Division JP2026116276A (ja) 2019-09-20 2026-02-13 遺伝子療法組成物および不整脈源性右心室心筋症の治療

Publications (2)

Publication Number Publication Date
JP2022549140A true JP2022549140A (ja) 2022-11-24
JP2022549140A5 JP2022549140A5 (cg-RX-API-DMAC7.html) 2023-09-22

Family

ID=72615856

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517343A Pending JP2022549140A (ja) 2019-09-20 2020-09-21 遺伝子療法組成物および不整脈源性右心室心筋症の治療
JP2026021870A Pending JP2026116276A (ja) 2019-09-20 2026-02-13 遺伝子療法組成物および不整脈源性右心室心筋症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2026021870A Pending JP2026116276A (ja) 2019-09-20 2026-02-13 遺伝子療法組成物および不整脈源性右心室心筋症の治療

Country Status (9)

Country Link
US (3) US20220389452A1 (cg-RX-API-DMAC7.html)
EP (1) EP4031672A1 (cg-RX-API-DMAC7.html)
JP (2) JP2022549140A (cg-RX-API-DMAC7.html)
KR (1) KR20220066914A (cg-RX-API-DMAC7.html)
AU (1) AU2020350140A1 (cg-RX-API-DMAC7.html)
CA (1) CA3151036A1 (cg-RX-API-DMAC7.html)
IL (1) IL291488A (cg-RX-API-DMAC7.html)
TW (1) TWI897882B (cg-RX-API-DMAC7.html)
WO (1) WO2021053222A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512483A (ja) * 2021-03-19 2024-03-19 ユーシーエル ビジネス リミテッド 遺伝子治療組成物及び不整脈原性右室心筋症の治療

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114450411A (zh) 2019-04-01 2022-05-06 特纳亚治疗股份有限公司 具有工程化衣壳的腺相关病毒
WO2021142267A1 (en) * 2020-01-08 2021-07-15 Scarpmap Llc Methods and computing system for processing ultrasound image to determine health of subdermal tissue
FI4103214T3 (fi) 2020-02-13 2026-07-03 Tenaya Therapeutics Inc Geeniterapian vektorit sydänsairauden hoitoon
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector
JP7415042B2 (ja) 2020-10-09 2024-01-16 テナヤ セラピューティクス, インコーポレイテッド プラコフィリン2遺伝子治療の方法および組成物
US11781156B2 (en) * 2020-10-09 2023-10-10 Tenaya Therapeutics, Inc. Plakophillin-2 gene therapy methods and compositions
BR112023021037A2 (pt) * 2021-04-12 2023-12-19 Univ California Terapia gênica para cardiomiopatia ventricular direita arritmogênica
WO2023159190A1 (en) * 2022-02-18 2023-08-24 Ginkgo Bioworks, Inc. Gene therapy for arrhythmogenic cardiomyopathy
IL315695A (en) * 2022-03-18 2024-11-01 Univ Florida Methods and compositions for treating RBM20-associated cardiomyopathy with a viral vector
EP4507713A4 (en) * 2022-04-11 2026-04-15 Tenaya Therapeutics Inc PLAKOPHILIN-2 BASED GENE THERAPY TREATMENT METHODS
US20260102513A1 (en) * 2022-09-21 2026-04-16 Rejuvenate Bio Gene therapy methods for arrhythmogenic cardiomyopathy
UY40442A (es) * 2022-09-22 2024-02-15 Biomarin Pharm Inc Tratamiento de la miocardiopatía arritmogénica con vectores de genoterapia con aav
CN116064612A (zh) * 2022-11-17 2023-05-05 百世诺(北京)医疗科技有限公司 肥厚型心肌病变异基因alpk3及其应用
CN122161621A (zh) * 2023-07-06 2026-06-05 加利福尼亚大学董事会 Alpk3心肌病的基因替代疗法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2792742A1 (en) * 2013-04-17 2014-10-22 Universitätsklinikum Hamburg-Eppendorf (UKE) Gene-therapy vectors for treating cardiomyopathy
WO2017083750A1 (en) * 2015-11-11 2017-05-18 Intrexon Corporation Compositions and methods for expression of multiple biologically active polypeptides from a single vector for treatment of cardiac conditions and other pathologies
WO2018208998A1 (en) * 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
WO2019060619A1 (en) * 2017-09-20 2019-03-28 The Regents Of The University Of California STRATEGY OF GENE THERAPY FOR RESTORING ELECTRICAL AND CARDIAC FUNCTION AND CARDIAC STRUCTURE IN ARYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY
DK3684423T5 (da) * 2017-09-20 2024-08-26 4D Molecular Therapeutics Inc Adeno-associerede virusvariantcapsider og fremgangsmåder til anvendelse deraf
CA3097375A1 (en) * 2018-04-27 2019-10-31 Universitat Heidelberg Modified aav capsid polypeptides for treatment of muscular diseases
CN109004092A (zh) 2018-06-29 2018-12-14 云谷(固安)科技有限公司 有机电致发光器件和有机电致发光装置
WO2022032226A1 (en) * 2020-08-07 2022-02-10 Spacecraft Seven, Llc Plakophilin-2 (pkp2) gene therapy using aav vector

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURR OPIN CARDIOL, vol. 32, no. 3, JPN6024032449, 2017, pages 275 - 282, ISSN: 0005908242 *
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 65, no. 14, JPN6024032450, 2015, pages 1438 - 1450, ISSN: 0005908241 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024512483A (ja) * 2021-03-19 2024-03-19 ユーシーエル ビジネス リミテッド 遺伝子治療組成物及び不整脈原性右室心筋症の治療

Also Published As

Publication number Publication date
KR20220066914A (ko) 2022-05-24
US20220389452A1 (en) 2022-12-08
IL291488A (en) 2022-05-01
TWI897882B (zh) 2025-09-21
US20240076696A1 (en) 2024-03-07
WO2021053222A1 (en) 2021-03-25
JP2026116276A (ja) 2026-07-09
US20250163470A1 (en) 2025-05-22
TW202126674A (zh) 2021-07-16
EP4031672A1 (en) 2022-07-27
CA3151036A1 (en) 2021-03-25
AU2020350140A1 (en) 2022-03-31

Similar Documents

Publication Publication Date Title
TWI897882B (zh) 右心室心律失常性心肌病之基因療法組合物及治療
US20240042059A1 (en) Gene therapy composition and treatment of right ventricular arrhythmogenic cardiomyopathy
US10501756B2 (en) Gene-therapy vectors for treating cardiomyopathy
US9938541B2 (en) AAV variant
US20230047424A1 (en) Gene therapy composition and treatment for myh7-linked cardiomyopathy
JP2025163022A (ja) 停止していない鼓動している心臓への薬物灌流
US20180099029A9 (en) Serca2 therapeutic compositions and methods of use
US20250099620A1 (en) Gene therapy composition and treatment for dystrophin-related cardiomyopathy
HK40112779A (en) Drug perfusion into an unarrested beating heart
WO2025155918A1 (en) Cardioprotective compositions and methods for atrial fibrillation
HK40077296B (en) Drug perfusion into an unarrested beating heart
HK40077296A (en) Drug perfusion into an unarrested beating heart
HK40036161A (zh) 腺相关病毒变异衣壳和其使用方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230913

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240820

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20241119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250501

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250730

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260213